Contrast-enhanced ultrasound (CEUS) is a specific form of ultrasound imaging performed with intravenous administration of microbubble contrast agents. It has been extensively used for liver tumor characterization and was recently added to the American College of Radiology Liver Imaging Reporting and Data System (CEUS LI-RADS). This paper describes technical recommendations for successful liver CEUS lesion characterization, and provides imaging protocol and Lexicon of imaging findings.
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide with an annual incidence of over 750,000, predominantly affecting patients with cirrhosis and chronic hepatitis [1] . Treatment options for HCC include surgery, local ablation, embolization, and hepatic transplantation which are more feasible and effective when performed in the early tumor stage. Therefore, early detection and accurate diagnosis of HCC have become increasingly important [2] . Current American Association for the Study of Liver Diseases (AASLD) guidelines for the treatment of hepatocellular carcinoma recommend ultrasound (US) for HCC surveillance, and computed tomography (CT) and magnetic resonance imaging (MRI) for diagnosis of HCC in patients with nodules detected during surveillance US [3] . The AASLD HCC diagnostic algorithm initially included CEUS with CT and MRI, but the CEUS was removed from the guidelines in 2010. This was due to the possibility of misdiagnosing intrahepatic cholangiocarcinoma (ICC) as HCC and was based on one retrospective study [4] . Since then, there have been multiple studies investigating the accuracy of CEUS for focal liver lesion characterization. These studies have shown that ICC often shows arterial phase rim enhancement, unusual for HCC, and washout which tends to be much earlier than that of HCC, and of marked degree [5, 6] . As a result, the most recent 2017 AASLD guidelines for the treatment of hepatocellular carcinoma acknowledged that although not used widely in North America, multiphasic contrast-enhanced ultrasound (CEUS) also can be used to diagnose HCC non-invasively, but further studies are needed [3] .
Imaging diagnosis of HCC can be challenging, especially in patients with advanced cirrhosis, in which structural and physiological alterations of the back-ground liver parenchyma can impair HCC detection and diagnosis [7] . It is also complicated by the variety of regenerative and dysplastic nodules seen in patients with cirrhosis [8] [9] [10] [11] . Furthermore, early HCC exhibits minimal neovascularization and typically does not manifest arterial hypervascularity at imaging, making its diagnosis challenging [12, 13] . In addition to the full spectrum of hepatocellular nodules, other nodules, such as hemangiomas, cysts, intrahepatic cholangiocarcinoma (ICC), metastases, as well as pseudo-lesions, such as confluent fibrosis, perfusion alterations, focal fat deposition and sparing, further complicate liver imaging [14, 15] .
Patients with chronic liver disease are at risk for both HCC and ICC. Since ICC precludes transplantation, making differentiation between these tumors is critically important. Multiple investigators studied the differences in CEUS appearance of HCC and ICC with similar results [5, 6, 16, 17] . Both HCC and ICC demonstrate similar hyper-enhancement in the arterial phase on CEUS, but show drastically different behaviors on the delayed phase CEUS imaging with ICC washing out much sooner (typically < 60 s after contrast injection) and to a greater degree compared to HCC, which tend to washout late (> 60 s after contrast injection) and with mild washout degree. Han et al. demonstrated that at 3 min after injection contrast washout was detected in all ICCs, but in only 12.5% of HCC tumors (p < 0.001) [16] . They concluded that majority of HCCs can be characterized by observation of no or delayed weak washout. In contrast, more rapid washout was characteristic of ICC [16] . The authors also noted that there was no significant difference in the degree of ICC washout between patients with chronic hepatitis and those without. Li et al. demonstrated no difference between HCC and ICC appearance in the arterial phase of CEUS imaging [5] . However, similar to other studies, ICC demonstrated earlier washout onset compared to HCC (47.9 s vs. 90.9 s, respectively). When the authors combined early washout onset and marked washout degree as diagnostic criterion for ICC, the CEUS demonstrated 78.8% sensitivity, 88.0% specificity, 81.3% PPV, 86.3 NPV, and 84.3% diagnostic accuracy. Significant differences in timing and degree of contrast washout on CEUS between ICC and HCC were also confirmed in two large studies by Wildner D et al. [6, 17] .
In order to improve liver imaging in patients at risk for HCC, an expert panel of the American College of Radiology (ACR) introduced the ''Liver Imaging Reporting and Data System'' (LI-RADS), a system of standardized terminology and criteria for interpretation and reporting of liver observations in livers at risk for HCC [18] . LI-RADS uses a diagnostic algorithm, based on a lexicon of precisely defined terms and imaging features, to assist radiologists in assigning the probability of HCC to nodules visualized in the at risk liver. Originally developed for CT and MRI, LI-RADS has been extended in 2016 to include CEUS [19] [20] [21] . LI-RADS was developed based on evidence, expert opinion and a desire to be consistent with the other existing diagnostic systems in the United States, namely, the imaging criteria embedded in the AASLD HCC clinical practice guidelines and the imaging criteria included in the Organ Procurement and Transplantation Network (OPTN) transplant policy [22, 23] .
Contrast-enhanced ultrasound can significantly improve liver imaging in patients at risk for HCC development. Ultrasound imaging is portable, provides realtime imaging with high temporal and spatial resolution and uses no ionizing radiation [24] [25] [26] . After detection of a new liver nodule on surveillance US, there is a potential for immediate characterization with CEUS instead of scheduling a CT and MRI at a later time or date. In patients at risk for HCC, CEUS has specificity and sensitivity for HCC diagnosis comparable to CT and MRI [27] . It also is less expensive than CT and MRI, and is more readily available worldwide. Ultrasound contrast agents are extremely well tolerated and demonstrate no nephrotoxicity, making them exceptionally safe [28] [29] [30] [31] . CEUS of the liver becomes even more relevant with the recent FDA approval of a second-generation ultrasound contrast agent Lumason (Bracco Diagnostics Inc., Monroe Township, NJ) for liver imaging, making focal liver lesion characterization with CEUS the obvious next step after lesion detection on surveillance ultrasound.
This manuscript was prepared to provide readers with detailed description of CEUS technique and instrumentation used for CEUS LI-RADS focal liver nodule characterization in patients at risk for HCC and to provide a uniform lexicon to be used for imaging findings reporting.
CEUS LI-RADS
CEUS LI-RADS currently includes 8 categories characterizing focal liver observations based on HCC probability, from definitely benign (LR-1) to definitely HCC (LR-5), and probably or definitely malignant, but not necessarily HCC (LR-M). It also includes LR-NC category for observations that are not categorized due to image degradation or omission and LR-TIV category for observations with tumor in vein.
The details of categories, algorithm, major and ancillary features of CEUS LI-RADS are available on the ACR website (https://www.acr.org/Quality-Safety/ Resources/LIRADS).
Indications for CEUS
Although the entire liver is evaluated on the B-mode scan to determine if there are observations or nodules that should be evaluated with CEUS, generally two-to-three nodules represent the maximum that can be thoroughly characterized in a CEUS examination. Further, if HCC or malignancy is shown on CEUS, staging the disease with CT or MR scan prior to treatment is usually recommended. CEUS is also excellent for evaluating specific nodules or problems that have previously been identified on either CT or MR imaging [32] .
In patients at risk for HCC, CEUS can be used for the following indications:
Assess nodules ‡ 10 mm detected on surveillance US. Assess LR-3, LR-4, and LR-M observations detected on prior CT or MRI.
Detect arterial phase hyperenhancement (APHE) when mistiming is suspected as the reason for its absence on prior CT or MRI. CEUS is most reliable when assessing nodules ‡ 10 mm visible on pre-contrast B-mode images. In select cases, expert CEUS examiners, at their discretion, can perform CEUS to characterize smaller nodules or nodules occult on pre-contrast B-mode ultrasound using anatomical landmarks, image fusion or repeat contrast injections. Such characterization requires substantial experience and expertise. It is outside the purview of CEUS LI-RADS v2016 and v2017. Both treatment response assessment and imaging of observations not visible on pre-contrast B-mode may be addressed in CEUS LI-RADS v2020.
Technical recommendations

Examiner training
Appropriate ultrasound examiner and reader training are of paramount importance for successful CEUS implementation. Currently, the most robust training guidelines on CEUS are those developed by the EFSUMB [33] . They define three levels of training and recommend that CEUS should be performed by operators at Level 2 competence level or higher, who is able to Perform a thorough CEUS examination of the liver including documentation and appropriate cine loop storage during all relevant contrast enhancement phases.
Recognize focal lesions and vascular disorders and be proficient in identifying appropriately the conditions for CEUS investigation. The practice of CEUS also requires knowledge of ultrasound contrast agent administration and contraindications and the skill to handle possible side effects, such as allergic and cardiopulmonary reactions.
CEUS imaging Equipment
Ultrasound scanners equipped with appropriate software and hardware packages for contrast-enhanced imaging must be used. CEUS imaging is performed by separating signal from soft tissues that exhibit linear resonance under insonation from microbubbles, which are characterized by significant amount of non-linear resonance under the same conditions. These two signals (linear US signals from soft tissues and non-linear US signals from microbubbles) can be separated using various, often proprietary combinations of pulse inversion, frequency, and amplitude modulation. As a result, modern ultrasound scanners allow near perfect soft tissue cancelation in the contrast-specific imaging mode to produce predominantly microbubble images. This successful soft tissue cancelation will produce near complete disappearance (black screen) of soft tissue signal in the CEUS window, which is normal without the presence of intravenous microbubbles and should not be mistaken for system malfunction (Fig. 1) .
To minimize the disruption of the microbubbles, CEUS imaging is performed at low acoustic pressures with mechanical index (MI) ranging from 0.05 to 0.3. For comparison, routine ultrasound B-mode imaging is performed with MI greater than 1 and Doppler ultrasound with even higher levels (usually around MI 1.4), which would be detrimental for microbubbles. In addition to decreasing microbubble destruction, low MI imaging is helpful to reduce unwanted tissue harmonics, facilitating clear detection of contrast signals and improving signal-to-noise ratio.
Contrast agents
Currently, there are two purely intravascular ultrasound contrast agents with proven track record in liver imaging available for clinical use in the USA. Medical Imaging Inc., N. Billerica, MA). This agent is supplied as a single 2-mL clear glass vial containing a lipid blend and 6.52 mg/mL octafluoropropane in the headspace. Definity vials are activated by shaking for 45 s using a proprietary VIALMIX activation device. This agent is approved by the FDA for use in echocardiography in the USA. Liver imaging with Definity is considered off-label in the USA, but can be performed, if medically indicated.
Another purely intravascular agent Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, GE Healthcare, Princeton, NJ) is available for clinical use in the USA, but the documentation of successful use of this agent for liver imaging is lacking.
It should be noted that the current version of CEUS LI-RADS is based on use of purely intravascular contrast agents listed above. Use of the newer contrast agent Sonazoid (perflubutane microbubbles within a phosphatidyl serine shell, GE Healthcare, Oslo) is currently limited to Japan, South Korea, Denmark, and Norway where this agent is approved for clinical use. This agent demonstrates prolonged liver uptake due to increased stability of the shell and active phagocytosis by Kupffer cells. It has a potential of significantly improving diagnostic accuracy of CEUS and its use may be addressed in CEUS LI-RADS v2020.
Safety considerations
Microbubble contrast agents are well tolerated with only rare adverse events, as shown by nearly two decades of experience. Ultrasound contrast agents have no known renal toxicity in approved doses [34] . Large post-marketing studies performed in response to an FDA black box warning placed in 2007, confirmed a very low rate of adverse effects [35] [36] [37] . This led to substantial softening of contraindications and removal of a previously mandated 30-min monitoring period after administration of microbubble contrast agent.
A large retrospective multi-center study of the safety of Definity (66,164 doses) and Optison (12,219 doses), including over 10,000 doses to critically ill patients, showed severe allergic reactions in only eight patients (0.01% incidence) and allergoid reactions in only four patients (0.006% incidence) [38] . Another large retrospective study of 16,025 patients receiving Definity or Optison demonstrated overall adverse effect rate of 0.12% and the incidence of serious events (with no fatalities) of 0.031% [39] .
Safety data for Lumason are gleaned from postmarketing surveillance and clinical experience with SonoVue, the name by which Lumason is marketed outside the United States and has been available since 2001. In post-marketing surveillance of 1,651,451 patients exposed to SonoVue from April 1, 2001 through December 31, 2010, 217 serious adverse events were reported (0.013% incidence), with 162 being allergy-like or anaphyllactoid (0.0098% incidence) [40] . Even though adverse reactions are extremely rare, similar to CT and MRI contrast agents, all microbubble injections should be performed in appropriate settings and supervised by a board-certified physician. Resuscitation equipment and trained personnel should be immediately available to the patient during each CEUS exam [41] . Allergic reactions to ultrasound contrast agent, they should be managed in accordance to standard contrast guidelines as described in the ACR manual on contrast media [34] .
Patient positioning and precontrast examination
Patients should first undergo baseline US imaging to identify the observation/nodule and select the appropriate acoustic window for CEUS. Generally, the patient is positioned supine with the right arm in abduction. Having the sonographer/physician seated makes performing the exam easier and introduces less motion. The transducer is positioned in an approach whereby pre-contrast B-mode imaging best defines the lesion(s). Intercostal imaging may be the preferable approach for many lesions. As a general guide, it is often better to image in the longitudinal (sagittal or coronal) plane because this keeps the movement from breathing within the scan plane. Whatever the chosen approach, it should allow the target liver observation to be continuously visible during scanning. After appropriated patient position is established and acoustic window selected, B-mode images and measurements of observation, as well as sweeps through target focal liver observation in the transverse and sagittal planes should be acquired.
Contrast agent administration
After satisfactory patient positioning is achieved and precontrast imaging performed, the microbubble contrast agent bolus is injected intravenously.
Contrast agent dose Recommended dose of ultrasound contrast agents for liver imaging is 2.4 mL of Lumason or 0.2 mL of Definity. There are several factors that could influence dose of ultrasound contrast for a particular examination. In patients with low BMI, dose of contrast could be decreased by 20-30% to avoid overenhancement of the liver, which complicates detection of mild contrast washout. Imaging of very superficial liver lesions with higher-frequency probes will require contrast dose increase up to 4.8 mL of Lumason or 0.4 mL of Definity. In addition to patient factors, the contrast dose could be adjusted based on the sensitivity of the equipment used for CEUS examination. However, these contrast dose adjustments are infrequent and default doses of 2.4 mL of Lumason or 0.2 mL of Definity will provide appropriate contrast enhancement in the majority of patients.
Contrast agent injection Contrast injection should be performed through an IV line, preferably 20G, to avoid bubble destruction. Injection through central venous lines and infusion ports is acceptable as long as all safety and aseptic requirements are met. Use of the central venous lines and infusion ports will shorten the contrast arrival time. Contrast bolus should be delivered over 2-3 s. Care should be taken to prevent increase in contrast syringe pressure, since this can destroy the microbubbles within the syringe, leading to reduced enhancement and impaired image quality. The bolus of contrast should be immediately followed by a 5-10 mL normal saline flush delivered at the rate of approximately 2 mL/s.
Contrast timer If the contrast injection is performed into IV line extension, the scanner's contrast timer is usually started at the end of contrast injection (immediately prior to or simultaneous with onset of saline flush). However, if the contrast injection is performed directly into the peripheral IV catheter, the scanner's contrast timer is usually started at the beginning of contrast bolus injection. Regardless of the IV setup, start of the contrast timer should be kept consistent to avoid mistiming of contrast washout.
Suggested imaging parameters
Imaging should be performed in a dual screen format showing a low MI B-mode image alongside the contrastonly display to provide anatomic guidance and to ensure that target lesion is kept within the field of view during CEUS. One of the drawbacks of the dual screen technique is that both B-mode and contrast images are created using same low MI technique, resulting in significant degradation of B-mode image quality. Alternatively, CEUS imaging could be performed in contrastonly mode or using contrast overlay on top of B-mode images. These methods are rarely used in clinical practice and could complicate analysis of CEUS images.
Users should refer to the ultrasound scanner manufacturer manuals and, if needed, obtain additional technical support from the manufacturers, to ensure proper system settings before undertaking CEUS studies.
Transducer selection
Selecting an appropriate ultrasound transducer is critically important for successful CEUS examination. The transducer choice is usually based on the depth of the examined lesion and the characteristics of the acoustic window. Although most ultrasound scanners have multiple transducers that can be used for liver imaging, not all of them will support low MI contrast-specific imaging. The majority of US scanners have it enabled on curved array probes operating between 1 and 9 MHz and on some higher-frequency linear transducers. It should be noted that all clinical ultrasound contrast agents are optimized to resonate at relatively low frequencies and the use of the higher-frequency transducers require increase in contrast agent dose, which is usually doubled for imaging with linear transducers. As a general rule, CEUS liver imaging should be performed with a curved array transducer at a frequency of around 3-4 MHz to maximize contrast signals, with higher-frequency linear transducers reserved for small superficial lesions.
Depth of penetration and focal zone
Depth of penetration of CEUS is typically less than B-mode imaging due to increased microbubble scatter of and increased signal attenuation from the microbubbles in the near field (self-shadowing) and low MI used for contrast-specific imaging. To achieve the most optimal results, the acoustic window should be carefully selected allowing the examined lesion to be scanned as close to the transducer as possible, maintaining approximately 2 cm distance from the transducer to minimize potential image degradation from excessive microbubble destruction in the near field.
Appropriate placement of the focal zone is another very important step to ensure the high quality of CEUS imaging. To achieve an appropriate balance between nearfield contrast destruction and appropriate penetration, the focal zone should be positioned just deep to the target lesion for most ultrasound scanners (Fig. 2B) . However, deeper focal zone placement might be used to achieve a more uniform acoustic field, which improves sensitivity to the contrast agents (Fig. 2C) . Positioning focal zone very far from the transducer will generally require an increase of MI to improve signal intensity and depth of penetration. This will result in increased destruction of the microbubbles in the near field, degrading near field image quality and occasionally imitating contrast washout in the late phase. Positioning the focal zone too close to the transducer will generally result in a decrease of MI to preserve microbubbles from excessive degradation in the near field (Fig. 2D) . As a result, the overall signal intensity and depth of penetration will be decreased, resulting in significant signal loss in deeper regions.
Gain
Gain settings allow the examiner to adjust both B-mode and CEUS signal amplification. In general, results of gain changes in CEUS are similar to the effects seen in Color or Power Doppler modes. Setting gain too low will result in significant signal loss (Fig. 2E) . Setting gain too high will increase non-specific image noise, which appears as random signals distributed diffusely over the entire image field resulting in pseudo-enhancement (Fig. 2F ). The gain setting should be set as high as possible providing adequate soft tissue suppression without displaying pseudo-enhancement in the liver parenchyma, so the contrast mode image looks almost devoid of signal in preparation for contrast arrival. After the arrival of contrast, image gain can be adjusted accordingly. It should be noted that with some ultrasound scanners, it is normal to observe some artifacts produced by strong reflectors in the field of view, such as skin, muscle, and liver capsule and large vessels (Fig. 1) . This static pseudo-enhancement is usually easily recognizable and should not be suppressed by further decrease in CEUS image gain.
Dual/simultaneous calipers
Availability of simultaneous caliper display on both screens is ideal for observation/nodule localization, especially in situations where the lesion is not very obvious on B-mode images or to confirm hyperenhancement or washout is co-localizing with the observation/nodule (Fig. 3 ). This will serve to guide the operator's eye to arrival of contrast in the field of view, and to assess contrast enhancement, particularly of smaller and less obvious observations (i.e., isoenhancing or heterogeneously enhancing observations or nodules).
Imaging protocol
One of the great advantages of CEUS over CT and MRI is real-time imaging and this benefit must be used to its fullest. It should be noted, however, that continuous insonation of large portions of highly vascular tissues (i.e., liver) may result in excessive destruction of microbubbles and substantial decrease in the degree of contrast enhancement in the late phase. To maximize benefits of real-time CEUS imaging and to preserve enough microbubbles to allow late contrast washout detection, we recommend the following imaging strategy (Fig. 4) .
Imaging should be performed continuously from contrast injection until peak AP enhancement to capture peak AP enhancement and characterize the presence, intensity (hyper, iso, or hypo) and pattern of AP enhancement (diffuse, mosaic, rim, peripheral discontinuous globular). Alternatively, continuous imaging could be extended beyond peak AP enhancement until 60 s after contrast injection to determine presence of early washout. After 60 s, imaging should be performed intermittently (5-10 s every 30-60 s) to detect late washout and assess its degree. This technique will minimize microbubble destruction until microbubbles are cleared completely from the circulation (4-6 min after injection) and improve the ability to detect late washout and assess its degree.
Image recording should be performed continuously from first bubble arrival through peak AP enhancement as a minimum requirement. Optionally, the cine loop can be continued beyond the AP enhancement peak until at 60 s and with every intermittent (every 30-60 s) acquisition thereafter will be sufficient to document and evaluate the presence, timing, and degree of washout.
Sweeping the entire liver in the late phase can help to identify additional areas of washout as focal hypo-enhancing regions in the liver. However, in patients with advanced cirrhosis, the sensitivity of this approach may be compromised due to relatively poor background liver enhancement. If the area of washout is associated with a solid nodule visible on B-mode imaging, this nodule can be further characterized with an additional injection of contrast. If the area of washout is not associated with an identifiable nodule on B-mode ultrasound, radiologists/sonologists may at their discretion either proceed with further CEUS characterization or refer for an alternative diagnostic test. Repeat injection should be performed in accordance with contrast manufacturer guidelines. The maximum total contrast dose should not exceed that listed on the contrast agent package insert: 4.8 mL of Lumason or 20 lL/kg of the activated Definity [42, 43] . Please, refer to the specific contrast agent package insert for the most recent dosing information.
Patients with multiple liver nodules In general, up to two to three nodules can be successfully imaged in one patient. Imaging of multiple nodules often requires multiple injections and careful planning of patient positioning to maximize the use of limited acoustic windows. To accelerate microbubble clearance from the circulation Fig. 2 . CEUS focal zone and gain adjustments. B-mode image (A) demonstrates small indeterminate hypoechoic nodule (arrows). Focal zone adjustments: CEUS images with appropriate focal zone placement (circle) at the lower edge (B) or slightly deeper to the nodule (C) produced high-quality CEUS images demonstrating nodule with the absence of arterial phase enhancement, making it consistent with a cyst (LR-1). Also, note appropriate gain adjustment on both images (B,C). Positioning focal zone too close to the transducer (D) resulted in significantly decreased overall signal intensity and depth of penetration. Image gain adjustments Setting CEUS gain too low (E), even with appropriately placed focal zone, resulted in significant signal loss. Setting gain too high (F) increased non-specific image noise and produced pseudoenhancement in the liver cyst. Image reproduced with permission from the ACR. 
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A. Lyshchik et al.: Contrast-enhanced ultrasound of the liver between injections, the liver and the spleen may be briefly insonated with high MI (such as used in conventional B-mode or Color Doppler imaging). This approach will significantly improve visualization of arterial phase enhancement on subsequent injections by eliminating free circulating microbubbles from the prior injection.
Potential technical pitfalls and challenges
One of the most important CEUS limitations is the inability to image the entire liver in the arterial phase, since only a part of the organ, usually containing the region of interest with focal liver observation visible on the pre-contrast B-mode can be imaged with each injection. This limitation can be addressed by careful scanning of the entire liver in the late phase to detect focal areas of washout, which can be further evaluated in the arterial phase with repeat contrast injections. Some small lesions, usually less than 10 mm or lesions with subdiaphragmatic or very deep location can be challenging to visualize on CEUS. As a basic rule, if the lesion is difficult to clearly identify on pre-contrast B-mode imaging, it might be challenging to produce high-quality CEUS images. CEUS might also be limited in patients with high BMI and in the patients with severe hepatic steatosis, mainly due to substantial signal attenuation. In some patients, interfering bowel gas might limit lesion visualization.
Non-linear artifact, a CEUS phenomenon associated with pseudo-enhancement following ultrasound contrast agent injection, could also complicate CEUS imaging. It is caused by the non-linear propagation of sound through intervening microbubble-perfused tissue and is, therefore, most marked in hyperechoic objects in deep regions. Its original description is related to potential pseudo-enhancement of echogenic appearing treatment sites on CEUS following radiofrequency ablation [44] [45] [46] .
Lexicon of imaging findings
Each CEUS study should be evaluated using the following criteria:
Adequacy of CEUS exam:
The CEUS examination will be characterized as adequate when the entire region of interest, an observation or nodule can be unequivocally visualized for the entirety of the exam. Observations that cannot be categorized due to image degradation or omission are characterized as CEUS LR-NC (not categorizable).
Observation: A distinctive area with imaging features that differ from those of adjacent liver parenchyma. It may be a nodule or pseudolesion.
Nodule: A discrete mass of rounded or irregular shape.
It should be noted that CT and MRI LI-RADS use term ''observations'' to describe focal signal abnormalities. This is because many findings detected on CT and MRI may not represent true nodules. On CEUS, with exception of focal fatty infiltration and sparing, most of the focal liver observations are true nodules.
Observation location: Liver observation location using the Couinaud liver segment classification.
Observation size: The largest dimensions of the liver observation reported in three perpendicular planes, preferably on precontrast B-mode imaging. If observation margins are indistinct on B-mode imaging, measurements on the arterial phase CEUS images could be performed instead. It should be noted that CEUS measurements could overestimate true size of the observation, since it might be affected by contrast blooming artifact or inclusion of hyperenhancing surrounding liver parenchyma in the measurement.
Unequivocal diameter increase: Increase in the maximal diameter of an observation, measured on exams performed on different dates, which is not attributable to artifact, differences in technique or modality between the two exams, or measurement error. CEUS LI-RADS uses it as an ancillary feature to suggest malignancy.
Unequivocal diameter decrease: Unequivocal decrease in the maximal visualized diameter of an observation, measured on exams performed on different dates, which is not attributable to artifact, differences in technique or modality between the two exams, or measurement error. CEUS LI-RADS uses it as an ancillary feature to suggest benignity.
-Note: Currently, there are no universally accepted guidelines for tumor measurements on ultrasound. Therefore, we rely on the judgment to the ultrasound examiner to determine if changes in size are unequivocal (i.e., not attributable to artifact, differences in technique or modality between the two exams, or measurement error).
Diameter stability: No significant change in maximal diameter of an observation, measured on exams performed on different dates over ‡ 2 years and in the absence of treatment. CEUS LI-RADS uses it as an ancillary feature to suggest benignity.
Enhancement phases:
The dual blood supply of the liver from the hepatic artery (25-30%) and the portal vein (70-75%) gives rise to three overlapping vascular phases on CEUS study. While we use these enhancement phases in general terms, it is very important for CEUS evaluation to monitor the timing of washout in ''seconds'' as explained in washout features to accurately differentiate HCC from potential other malignancy. This is performed by having a contrast timer on the US screen which will allow for precise timing of any event during the CEUS examination.
-The hepatic arterial phase usually starts within 10-20 s after injection and continues to 30-45 s, depending on the individual's circulatory status. It provides information on the degree and pattern of the arterial vascular supply. This phase may occur very rapidly and the real-time nature of CEUS is needed to capture the essential features of the enhancement pattern, often best seen in a slow replay of a stored cine loop (Fig. 5 ). -The portal venous phase usually begins at about 30-45 s and lasts until 2 min after injection. -The late phase usually starts at about 2 min after contrast injection and lasts until the clearance of the microbubbles from the circulation (4-6 min after contrast injection).
Arterial phase enhancement:
The arterial phase enhancement of a liver nodule is assessed by comparing the intensity of the signal from a liver nodule with the signal from adjacent liver at the same depth, as evaluated on continuous image acquisition from the arrival of the first bubble to the peak of arterial phase enhancement.
-The degree of arterial phase enhancement should be characterized using four categories, as follows:
Hyperenhancement: Higher contrast agent signal intensity in the liver nodule as compared with the intensity of the adjacent liver at the same depth (Fig. 6 ). This feature can be considered present if it is demonstrated in either the entire nodule or in only a portion of the nodule. Iso-enhancement: Equivalent contrast agent signal intensity in the liver nodule as compared with the adjacent liver at the same depth (Fig. 7) . Hypo-enhancement: Less contrast agent signal intensity in the liver nodule as compared with the adjacent liver at the same depth (Fig. 8) .
No enhancement: Lack of contrast agent signal in the liver nodule (Fig. 9 ).
-The pattern of arterial phase enhancement should be characterized using four categories, as follows:
Enhancement in whole: enhancement of the entire nodule as compared to the surrounding liver parenchyma at the same depth (Fig. 6 ) Nodule-in-nodule enhancement: Increased enhancement of one or more inner nodules within a larger enhancing nodule (Fig. 10) . CEUS LI-RADS uses it as an ancillary feature to suggest malignancy, favoring HCC in particular. Rim-enhancement: enhancement mainly concentrated at the periphery of the liver nodule (Fig. 11 ). This is usually followed by rapid and marked washout. This is a typical feature of metastatic lesions and liver nodules with rim enhancement should be characterized as CEUS LR-M. Careful measurements of the lesion including and excluding rim enhancement, and compared with the baseline image, if well seen, are beneficial to determine precise location of rim enhancement. Peripheral discontinuous globular enhancement: Typical feature of hemangiomas (CEUS LR-1) that demonstrate interrupted areas of increased enhancement along the periphery of the lesion in the early arterial phase. This phenomenon is temporary and is usually followed by centripetal progression of the enhancement and sustained enhancement in the late phase (Fig. 12) .
Washout: Visually assessed temporal reduction in contrast agent signal intensity of a nodule relative to adjacent liver following initial enhancement, resulting in hypo-enhancement. At CEUS, all malignant nodules typically show washout-HCC, metastasis, intrahepatic cholangiocarcinoma (ICC), or hepatocholangiocarcinoma. Unlike CT or MRI with extracellular contrast agents, ICC and other fibrotic tumors do not show delayed central enhancement on CEUS. Washout is characterized by timing of washout onset and washout degree.
-Timing of washout onset: Timing of the first observation of washout reported in seconds after contrast bolus injection.
Early onset, detected < 60 s after contrast injection. CEUS LI-RADS uses early washout as a hallmark of CEUS LR-M lesions.
Late onset, detected ‡ 60 s after contrast injection. CEUS LI-RADS uses late washout as a hallmark of hepatocellular lesions.
-Washout degree, assessed by comparing degree of contrast enhancement in the nodule relative to surrounding liver.
Mild washout: is used when the liver nodule becomes hypoechoic relative to the liver but continues to show some contrast enhancement (Fig. 13) . CEUS LI-RADS uses mild washout that appears ‡ 60 s after injection as a hallmark of hepatocellular lesions. Nodules initially demonstrating mild washout might eventually become virtually devoid of contrast (''punchedout''). If this occurs after 2 min, the classification of wash-out as mild does not alter. Marked washout: is used when the liver nodule becomes virtually devoid of contrast (''punchedout'') within 2 min after contrast injection (Fig. 14) . CEUS LI-RADS uses marked washout as a hallmark of CEUS LR-M lesions [47] .
Mosaic architecture: Mosaic architecture refers to the presence within a mass of randomly distributed internal nodules differing in echogenisity on B-mode imaging and contrast enhancement intensity on CEUS (Fig. 15 ). This feature is characteristic of large HCCs and reflects the mosaic configuration with multiple confluent areas of tumor nodularity interspersed with fibrous septations, necrosis, hemorrhage, copper deposition, and fatty infiltration, as well as varying degrees of histologic differentiation [48] . CEUS LI-RADS uses it as an ancillary feature to suggest malignancy, favoring HCC in particular.
Tumor in vein:
Definite enhancing soft tissue in vein regardless of visualization of parenchymal mass/nodule. It must have definite enhancement in the arterial phase followed by washout (regardless of onset or degree) (Fig. 16 ).
- -Confirmation of arterial wave flow on spectral Doppler may be of additional help in differentiating tumor within vein from non-occlusive bland thrombus.
-Tumor in peripheral portal veins may be mistaken for tumor nodules, erroneously downstaging the patient. Avoidance is facilitated by real-time imaging while sweeping through the liver, especially in the portal phase, to depict the tubular configuration of the tumor and its continuity with more central portal or hepatic veins. A B-mode image demonstrates small hypoechoic nodule (arrows). B Early arterial phase image shows small discontinuous globular areas of increased enhancement along the periphery of the lesion. This is followed by centripetal progression of the enhancement (C) and sustained enhancement in the late phase (D). Image reproduced with permission from the ACR.
Discussion
To address the challenges of liver imaging in patients at risk for HCC and to provide a framework for assigning probability of HCC and other malignancy to imaging findings in patients at risk for HCC, the American College of Radiology developed LI-RADS, a system of standardized terminology and criteria for interpreting and reporting hepatic imaging findings in patients at risk for HCC. Initially designed for multiphasic CT and MRI it was recently extended to include CEUS. This manuscript represents a description of the technical aspects for CEUS and provides a detailed imaging protocol that should be used for uniformity of CEUS. It also provides a lexicon of imaging findings that should improve accuracy of image analysis and reporting. We are confident that systematic use of CEUS LI-RADS will decrease user-dependency of CEUS and provide a robust struc- tured diagnostic and reporting framework that optimizes clinical use of CEUS in patients at risk for HCC.
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